> One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss
> Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health
> One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss
> Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health